Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BMRA logo BMRA
Upturn stock ratingUpturn stock rating
BMRA logo

Biomerica Inc (BMRA)

Upturn stock ratingUpturn stock rating
$3.16
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: BMRA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $13

1 Year Target Price $13

Analysts Price Target For last 52 week
$13Target price
Low$
Current$3.16
high$

Analysis of Past Performance

Type Stock
Historic Profit -80.4%
Avg. Invested days 26
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 8.02M USD
Price to earnings Ratio -
1Y Target Price 13
Price to earnings Ratio -
1Y Target Price 13
Volume (30-day avg) -
Beta 0.33
52 Weeks Range 1.93 - 8.80
Updated Date 06/29/2025
52 Weeks Range 1.93 - 8.80
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.16

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -85.42%
Operating Margin (TTM) -108.13%

Management Effectiveness

Return on Assets (TTM) -35.99%
Return on Equity (TTM) -72.7%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 5377116
Price to Sales(TTM) 1.41
Enterprise Value 5377116
Price to Sales(TTM) 1.41
Enterprise Value to Revenue 0.95
Enterprise Value to EBITDA -5.42
Shares Outstanding 2545760
Shares Floating 2384045
Shares Outstanding 2545760
Shares Floating 2384045
Percent Insiders 10.13
Percent Institutions 5.8

Analyst Ratings

Rating -
Target Price 13
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Biomerica Inc

stock logo

Company Overview

overview logo History and Background

Biomerica Inc. was founded in 1971. Initially focused on producing medical products for gastroenterology, the company has expanded its offerings to include diagnostics and therapeutic products for various gastrointestinal (GI) diseases. It has grown through product development and strategic acquisitions.

business area logo Core Business Areas

  • Gastroenterology Diagnostics: Develops and commercializes diagnostic tests for gastrointestinal diseases, including Irritable Bowel Syndrome (IBS) and Helicobacter pylori (H. pylori) detection.
  • Gastroenterology Therapeutics: Offers therapeutic products aimed at treating gastrointestinal disorders, focusing on conditions like ulcerative colitis and Crohn's disease.

leadership logo Leadership and Structure

Zackary Irani serves as the Chairman, President, and CEO. The company operates with a functional organizational structure, emphasizing research and development, manufacturing, and sales & marketing.

Top Products and Market Share

overview logo Key Offerings

  • InPouchu00ae HSV: A rapid test for Herpes Simplex Virus (HSV) detection. Competitors include Quidel Corporation and Abbott Laboratories. Data regarding market share is difficult to obtain from public domain and not available.
  • hpylori test: A rapid test for Helicobacter pylori (H. pylori) detection in stool. Competitors include Abbott and Roche. Data regarding market share is difficult to obtain from public domain and not available.
  • IBDifferentiateu00ae: A diagnostic test to differentiate between ulcerative colitis and Crohn's disease. Competitors in this space include Prometheus Laboratories (acquired by Nestle Health Science). Data regarding market share is difficult to obtain from public domain and not available.

Market Dynamics

industry overview logo Industry Overview

The diagnostics and therapeutics market for gastrointestinal diseases is growing due to increasing prevalence of GI disorders, aging populations, and advancements in diagnostic technologies.

Positioning

Biomerica Inc. is positioned as a specialist in the gastrointestinal health market, focusing on developing and commercializing innovative diagnostic and therapeutic solutions. They compete with larger, diversified healthcare companies.

Total Addressable Market (TAM)

The global gastrointestinal drugs market is projected to reach $61.4 billion by 2027. The diagnostics market is estimated at $9 billion. Biomerica is positioned to capture a portion of these markets through its specialized product offerings.

Upturn SWOT Analysis

Strengths

  • Specialized focus on gastroenterology
  • Proprietary diagnostic and therapeutic technologies
  • Established distribution network
  • Strong brand recognition in niche markets

Weaknesses

  • Limited financial resources compared to larger competitors
  • High dependence on a few key products
  • Smaller sales and marketing team
  • Potential competition from major pharmaceutical companies.

Opportunities

  • Expansion into new geographic markets
  • Development of novel diagnostic and therapeutic products
  • Strategic partnerships with larger healthcare companies
  • Increasing demand for non-invasive diagnostic tests

Threats

  • Intense competition from established players
  • Regulatory hurdles for new product approvals
  • Changes in reimbursement policies
  • Technological obsolescence

Competitors and Market Share

competitor logo Key Competitors

  • ABT
  • ROCHE.SW
  • DGX

Competitive Landscape

Biomerica competes with significantly larger companies. Its competitive advantage lies in its specialization and niche product offerings, but it faces challenges in terms of resources and scale.

Growth Trajectory and Initiatives

Historical Growth: Historical growth trends require analysis of past financial statements from their SEC filings (e.g., 10-K reports).

Future Projections: Future growth projections are best found from investment analyst reports.

Recent Initiatives: Recent initiatives can be identified in press releases and investor presentations.

Summary

Biomerica Inc. is a niche player focused on gastroenterology diagnostics and therapeutics. While it has specialized expertise and established products, it faces competition from larger players. The company's growth depends on successful product development, strategic partnerships, and expansion into new markets, while guarding itself against competitive pressures and regulatory challenges.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Biomerica Inc. SEC Filings (10-K, 10-Q), Company Website, Industry Reports, Analyst Reports

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market share data is estimated based on industry reports and company presentations and may not be exact.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Biomerica Inc

Exchange NASDAQ
Headquaters Irvine, CA, United States
IPO Launch date 2005-01-03
CEO & Director Mr. Zackary S. Irani
Sector Healthcare
Industry Medical Devices
Full time employees 64
Full time employees 64

Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops, markets, and sells COVID-19 diagnostic tests to indicate if a person has been infected by COVID-19. The company was incorporated in 1971 and is headquartered in Irvine, California.